The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 94 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 3.5 mo · strongest signal: Exchange deficiency notice (Sep 2, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity, runway < 6 months) coexists with live selling machinery (atm program, convertible note, pipe, shelf filed). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
On 2 September 2026, Senti disclosed receipt of a Nasdaq Staff Delisting Determination Letter citing failure to cure minimum bid price, equity deficiency (now -$3.4M at 30 June 2026), and stockholders' equity below $2.5M; the company requested a Hearings Panel. On 4 September 2026 Senti amended its securities purchase agreement and filed an equity commitment letter referencing stockholders' equity deficiency, indicating ongoing PIPE negotiations. An S-3/A shelf amendment was filed 10 September 2026, and a Schedule 13D/A on 11 September 2026 suggests related-party participation.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 22, 2026 | ▼ Shelf filed | S-3/A filed 2026-09-22 filing | 31 |
| Sep 11, 2026 | · 13D amendment | Schedule 13D/A filed 2026-09-11 filing | 24 |
| Sep 10, 2026 | ▼ ATM program | “atm” language in S-3/A (EX-99.1) filed 2026-09-10 filing | 43 |
| Sep 10, 2026 | ▼ Shelf filed | S-3/A filed 2026-09-10 filing | 32 |
| Sep 4, 2026 | ▼ Convertible note | “convertible note” language in 8-K (EX-10.1) filed 2026-09-04 filing | 45 |
| Sep 4, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (EX-10.2) filed 2026-09-04 filing | 42 |
| Sep 4, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.1) filed 2026-09-04 filing | 38 |
| Sep 4, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-10.1) filed 2026-09-04 filing | 35 |
| Sep 4, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-09-04 (accepted 06:01 ET) filing | 27 |
| Sep 2, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-09-02 (accepted 16:29 ET) filing | 61 |
| Sep 2, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (8-K) filed 2026-09-02 filing | 58 |
| Sep 2, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-09-02 filing | 52 |
| Sep 2, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-02 filing | 48 |
| Sep 2, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-09-02 filing | 47 |
| Sep 2, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.1) filed 2026-09-02 filing | 38 |
| Sep 2, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-09-02 filing | 35 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~3.5 months runway: liquidity $12,980,000 (cash $6,463,000 + investments $6,517,000) as of 2026-06-30, burn $44,063,611/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 38 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-3,401,000 as of 2026-06-30 filing | 31 |
SDST Stardust Power Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · JUNS JUPITER NEUROSCIENCES, INC. · screener →